ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events

Hørsholm, Denmark, 2 September 2025 – ExpreS2ion Biotech Holding AB’s (“ExpreS2ion” or the “Company”) CEO, Bent U. Frandsen, recently presented at two investor-focused events: Økonomisk Ugebrev’s Life Science Conference (27 August 2025) and ProHearings’ Life Science Seminar (29 August 2025). These appearances provided an opportunity for the Company to share updates on its breast cancer vaccine candidate ES2B-C001, as well as its broader pipeline and financial position, with a wide audience of investors, analysts, and stakeholders.

Event Highlights
At both events, Mr. Frandsen highlighted:

• Phase I Clinical Progress: The first patients have been dosed in the ongoing Phase I trial of ES2B-C001 in HER2+ and HER2-low breast cancer. Up to 27 participants are expected, with interim data anticipated in mid-2026.

• Pipeline Breadth: ExpreS2ion continues to advance multiple vaccine programs, including 11 malaria vaccine trials with the University of Oxford and consortium-driven influenza and Nipah virus vaccine projects.

• Market Opportunity: ES2B-C001 addresses a global market for HER2-positive breast cancer therapies estimated at over USD 13 billion annually.

• Financial Position: The Company reported strong growth in CRO and grant revenues (+61% YoY in H1 2025) while maintaining disciplined cost control.

• TO 11 Warrants (ProHearings presentation): The Company also referred to the TO 11 warrants during its ProHearings presentation. Full details, including terms, timetable, and documentation, are available on ExpreS2ion’s investor website at https://investor.expres2ionbio.com/rights-issue-2024/.

The Økonomisk Ugebrev and ProHearings sessions also included live Q&A discussions, giving investors the opportunity to ask about clinical progress, business development, and financial outlook.

The full presentation decks used during the conferences are available on the Company’s investor site here. Video recordings of both events, including the Q&A sessions, are also available at the same link.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com

Läs mer på Cision